About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and ...
Asthma, Chronic Obstructive Pulmonary Disease (COPD), allergy and nasal therapies see sustained growth amid severe to very ...
Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...
The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...
Successful management of denture-associated candidiasis relies heavily on mechanical disinfection rather than pharmacologic ...
The eight recommended digital technologies are: Asthmahub, Asthmahub for parents, AsthmaTuner, Digital Health Passport, Luscii, myAsthma, RDMP (Respiratory Disease Management Platform) and Smart ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
The treatment of chronic obstructive pulmonary disease (COPD) has been guided for decades by robust clinical practice guidelines (CPGs), such as NICE1 and GesEPOC,2 as well as international ...
A recent study published in the journal of Radiology showed that dynamic chest radiography (DCR) may serve as an effective ...
Regarding who can use these inhalers, NHS guidelines state: "Most adults can use beclometasone inhalers for asthma or COPD.
Objectives In patients with chronic obstructive pulmonary disease (COPD), severe exacerbations (ECOPDs) impose significant morbidity and mortality. Current guidelines emphasise using ECOPD history to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback